CD274 and triple-negative breast carcinoma: Furthermore, it is also recommended for the treatment of patients with recurrent or metastatic small-cell neuroendocrine carcinoma of the cervix, advanced triple-negative breast cancer with PD-L1 expression in ≥1% tumor-infiltrating immune cells and for metastatic urothelial carcinoma patients who are ineligible for any platinum-containing chemotherapy irrespective of the PD-L1 expression in their tumors or who are ineligible for cisplatin chemotherapy [8,9,10,11].